International Programs
The Proctor Foundation was founded in 1947 for the specific aim of eradicating trachoma worldwide. Since that time, it has evolved into a major research and teaching unit at UCSF, with the Foundation’s goal remaining the prevention and treatment of blindness worldwide. The International Programs division at Proctor has taken over the original goal of the foundation and has focused on the prevention of blindness programs around the world.
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST)
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU)
For more please visit: https://clinicaltrials.ucsf.edu/trial/NCT03816397
AVENIR I and II
AVENIR I was designed to compare age-based approaches to targeting azithromycin mass drug administration (MDA) to reduce mortality among children in Niger. In addition, AVENIR I included substudies to determine optimal approaches to implementation as a program. In AVENIR II, we are expanding the azithromycin MDA for child survival nationwide in Niger and developing rigorous approaches to monitoring mortality and antimicrobial resistance in a programmatic setting.
PI: Kieran O'Brien, PhD and Thomas M. Lietman, MD
For more please visit: https://pubmed.ncbi.nlm.nih.gov/33926403/
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the CORNea
This study takes advantage of international collaborations and recent advances in genomic technologies to identify pathogens and provide regional AMR profiles to these infections. The results of this study may help to decrease AMR proliferation and improve diagnostics and therapeutic approaches for infectious keratitis, thus reducing the worldwide burden of corneal blindness.
For more please visit: https://doanlab.ucsf.edu/research/capricorn
FAST: Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment
This is a sub-analysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial, which was an international, multicenter, block-randomized, observer-masked, comparative effectiveness trial comparing MTX and MMF as initial treatments for non-infectious uveitis. This study was undertaken at multiple referral centers in India, the United States, Australia, Saudi Arabia and Mexico between 2013 and 2017.
For more please visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256664/
Ocular Rosacea microBiome Study
The Ocular Rosacea microBiome Study (ORBS) is a pioneering international, multi-site research initiative designed to explore the impact of different dosing strategies of doxycycline on the treatment of symptomatic ocular rosacea. This parallel-arm randomized clinical trial will investigate sub-microbial versus antibiotic dosing of doxycycline compared to a placebo, aiming to enhance our understanding of the disease and improve therapeutic outcomes.
For more please visit: https://proctor.ucsf.edu/orbs
Parasitic Ulcer Treatment Trial (PUTT)
A randomized trial to determine if topical steroids are safe and effective for improving vision in acanthamoeba keratitis. The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy.
For more please visit: https://clinicaltrials.ucsf.edu/trial/NCT06213649#:~:text=The%20Parasitic%20Ulcer%20Treatment%20Trial,(AK)%20will%20improve%20vision.
Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes
SCORPIO is an international, multi-site study that takes advantage of advances in genomic technologies to enhance our understanding of conjunctivitis epidemics globally by identifying the pathogens involved, characterizing the evolution of pathogen genomes across time and space, and defining the immune responses to these infections. We hope to improve prevention methods and help to curtail spread, thus reducing the burden on cost and human ocular morbidity.
PI: Thuy Doan, MD PhD
For more please visit: https://doanlab.ucsf.edu/research/scorpio
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
Steroids and Cross-linking for Ulcer Treatment (SCUT II) is an international, randomized, double-masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus collagen cross-linking (CXL), as well as to further evaluate findings from subgroup analyses of SCUT. Patients presenting to the Aravind Eye Care System (India), Kaiser Permanente Northern California (USA), or the University of California, San Francisco (USA) with smear-positive and/or culture-positive typical (i.e. non-Nocardia or Mycobacteria) bacterial corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of three treatment groups:
For more please visit: https://clinicaltrials.ucsf.edu/trial/NCT04097730
Trachoma mHealth Study
A study to determine the feasibility and validity of integrating visual acuity assessment and autorefraction with trachoma surveys in the Peruvian Amazon.
Use of Serosurveillance to Support the Trachoma Elimination Endgame
Seroepidemiology is the use of antibodies in blood to measure infectious disease transmission. The Proctor Foundation is working colleagues at the US Centers for Disease Control and Prevention, the World Health Organization, and The Carter Center to study how populations' antibody signatures to Chlamydia trachomatis, the causative pathogen for trachoma, change as they approach and achieve trachoma elimination. This NIH-funded study is harmonizing measurements collected from over 60,000 children ages 1-9 years old throughout Africa, Asia, and Latin America. Faculty at Proctor are using this immense resource to develop statistical methods that track changes in C. trachomatis transmission and determine when transmission is sufficiently low that programs could halt population-level interventions for trachoma. The goal is to inform WHO guidelines for use of serology to monitor trachoma elimination.
For more please visit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038749/
Village Integrated Eye Worker (VIEW) trial I & II
A cluster-randomized trial to determine if community-based screening for eye diseases can improve vision of the community. The objective of this study is to assess the efficacy of antibiotic ointment prophylaxis to reduce incidence of corneal ulceration and subsequent blindness. We compare communities randomized to receive an intensive health promotion effort aimed at early prophylaxis for corneal abrasion to communities receiving standard-of care (no active intervention).
PI: Thomas M. Lietman, MD & Jeremy Keenan, MD, MPH
For more please visit:
https://globalprojects.ucsf.edu/project/village-integrated-eye-workers-trial